Mirikizumab (IL23A) Antibody, Monoclonal | 10-858

Mirikizumab (IL23A) Antibody, Monoclonal | 10-858 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / IL23A [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG4-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: LY-3074828

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Mirikizumab is humanized IgG4 monoclonal antibody that targets p19 subunit binding to IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn's disease (CD) , of which the treatment of moderate to severe plaque psoriasis is already in phase III clinical practice.